SYNE2 and non-small cell lung carcinoma: Moreover, considering the frequent alterations of THSD7B, SYNE2, GRM3, and FLNC in lung squamous cell carcinoma and lung adenocarcinoma (Figure S6), we investigated the applicability of ITS to NSCLC patients treated with ICIs.